United Therapeutics Corp/ US91307C1027 /
| 2024-11-15 9:59:57 PM | Chg. -22.69 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 363.27USD | -5.88% | 46,043 Turnover: 16.75 mill. |
-Bid Size: - | -Ask Size: - | 16.22 bill.USD | - | 17.26 |
Assets
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 545.7000 | 699.7000 | 738.5000 | 731.6000 | 780.9000 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | 502.7000 | 442.6000 | 767.5000 | 1,149.6000 | 1,649.9000 | ||||||
| Fixed Assets | 1,431.5000 | 1,633 | 2,048.9000 | 2,447.8000 | 2,845.5000 | ||||||
| Inventories | 107.9000 | 101 | 93.4000 | 86.5000 | 93.8000 | ||||||
| Accounts Receivable | 297.1000 | 175.7000 | 151.4000 | 157.4000 | 198.7000 | ||||||
| Cash and Cash Equivalents | 705.1000 | 669.2000 | 738.4000 | 738.7000 | 894.8000 | ||||||
| Current Assets | 1,447.9000 | 1,768 | 1,864.5000 | 2,167.2000 | 2,323.6000 | ||||||
| Total Assets | 2,879.4000 | 3,401 | 3,913.4000 | 4,615 | 5,169.1000 | ||||||
Liabilities
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | - | - | - | ||||||
| Long-term debt | 250 | 250 | 600 | 800 | 800 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 600 | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 777.6000 | 612.4000 | 1,133 | 1,219.8000 | 1,210.2000 | ||||||
| Share Capital | .7000 | .7000 | .7000 | .7000 | .7000 | ||||||
| Total Equity | 2,101.8000 | 2,788.6000 | 2,780.4000 | 3,395.2000 | 3,958.9000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 2,879.4000 | 3,401 | 3,913.4000 | 4,615 | 5,169.1000 | ||||||
Income Statement
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,725.3000 | 1,627.8000 | 1,448.8000 | 1,483.3000 | 1,685.5000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 814.9000 | 805.4000 | -187.6000 | 593.6000 | 555.9000 | ||||||
| Interest Income | -9 | 14.7000 | 0.0000 | 5.1000 | -1.9000 | ||||||
| Income Before Taxes | 769.5000 | 758.9000 | -165 | 638.9000 | 593.9000 | ||||||
| Income Taxes | -351.6000 | -169.7000 | 60.5000 | -124.1000 | -118.1000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 417.9000 | 589.2000 | -104.5000 | 514.8000 | 475.8000 | ||||||
Per Share
Cash Flow
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 474.2000 | 778.4000 | -206.6000 | 755.7000 | 598.2000 | ||||||
| Cash Flow from Investing Activities | -835.6000 | -820.6000 | -335.4000 | -738.5000 | -486.9000 | ||||||
| Cash Flow from Financing | 43.3000 | 6.3000 | 611.2000 | -16.9000 | 44.8000 | ||||||
| Decrease / Increase in Cash | -317.9000 | -35.9000 | 69.2000 | .3000 | 156.1000 | ||||||
| Employees | 800 | 860 | 920 | - | - | ||||||
